Tolvaptan
Orphan DrugFDA Approved
Description
Tolvaptan is a selective vasopressin V2-receptor antagonist indicated for slowing kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). It has been studied for use in juvenile nephronophthisis due to similar cystic kidney pathology. The drug works by blocking vasopressin receptors in the kidney collecting duct, reducing cyst growth and preserving renal function.
Indications & Therapeutic Use
Autosomal dominant polycystic kidney disease, juvenile nephronophthisis (investigational)
Linked Diseases:
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Tolvaptan
| Generic Name | Tolvaptan |
| Brands | 1 brand available |
| Active Ingredient | Tolvaptan |
| Drug Class | Autosomal dominant polycystic kidney disease |
| Manufacturer | Otsuka Pharmaceutical |
| Dosage Forms | Oral tablet 15mg, 30mg, 45mg, 60mg, 90mg |
| Medical Code | C03XA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01214421 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes